Author:
Moran Kellyn,Null Kyle,Huang Zhongwen,Lissoos Trevor,Kane Sunanda
Funder
Takeda Pharmaceuticals U.S.A.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference11 articles.
1. Moran K, Null K, Huang Z, Lissoos T, Kane S. Retrospective claims analysis indirectly comparing medication adherence and persistence between intravenous biologics and oral small-molecule therapies in inflammatory bowel diseases. Adv Ther. 2019;36:2260–72.
2. Pope J, Keystone E, Jamal S, et al. Persistence of tofacitinib in the treatment of rheumatoid arthritis in open-label, long-term extension studies up to 9.5 years. ACR Open Rheumatol. 2019;1:73–82.
3. Harnett J, Gerber R, Gruben D, Koenig AS, Chen C. Evaluation of real-world experience with tofacitinib compared with adalimumab, etanercept, and abatacept in RA patients with 1 previous biologic DMARD: data from a U.S. administrative claims database. J Manag Care Spec Pharm. 2016;22:1457–71.
4. Bressler B, Haraoui B, Keystone E, Sette A. Optimizing use of tumor necrosis factor inhibitors in the management of immune-mediated inflammatory diseases. J Rheumatol Suppl. 2010;85:40–52.
5. Kane S, Dixon L. Adherence rates with infliximab therapy in Crohn’s disease. Aliment Pharmacol Ther. 2006;24(7):1099–103.